Preparing healthcare companies for success
in the value-based economy

New Access Meter Report

more info >


Real Endpoints brings a wide range of strategic and operational market access solutions to our clients.

more >


Real Endpoints is a thought leader within the pharmaceutical industry. We actively publish and lead panels and are frequently quoted in the press.

more >

News and Events

NewYorkBio 2019 Annual Meeting

Panelist: Jeff Berkowitz

Real Endpoints

PANEL DISCUSSION I: Impact of Pricing and Policy on the Next Decade of Therapeutic Innovation

May 14, 2019
9:30am ET

Financial District, New York, NY

event >

Paying for Pharmaceutical Value: The Problem of a One-Size-Fits-All Definition

by Roger Longman

The industry has plenty of ways to define value. Thousands of academic and corporate health economists busily grind out cost-effectiveness analyses. CMS has designated five "compendia" as guides for reimbursable value, despite bizarrely opaque decision-making behind the compendias' choices.

April 12, 2019

In Vivo

news >

AMCP Annual Meeting 2019 – Financial Models to Manage Drug Spend of Gene Therapy

Jane Barlow, MD, MPH, MBA

Real Endpoints

Innovative and novel financing and reimbursement strategies may be needed to support sustainable patient access to these new treatments. During this session, managed care and provider strategies for addressing gene therapy will be explored.

March 25, 2019

San Diego Convention Center, CA

event >

Recent Insights

view archive >

February 13, 2019

Examining New Payment Ideas for Curative Therapies

How can the health industry ensure that cutting-edge gene therapies and other curative treatments get to the patients that need them, without leaving payers financially exposed? Jane F. Barlow, MD, MPH, MBA, was a speaker at the FoCUS (Financing and Reimbursement of Cure in US) Project at MIT, during the session "Putting Theory into Practice" she was quoted saying the “accessibility issue lies largely with payers.” All payers are different, and “a lot has to do with how they manage risk in their population as well as the regulatory constraints."

read full insight article >

January 28, 2019

AstraZeneca strikes a ‘novel’ deal with Medicare plan to lower patient out-of-pocket costs

In a novel bid to lower medicine costs, a drug maker has agreed to adjust the discounts that a Medicare Part D plan will receive for a treatment based on how patients respond — and the deal automatically lowers out-of-pocket costs for patients, as well. “One of the major problems we have in getting drug therapy used by people who really need it is that, for those people who are on Medicare, who have to pay co-insurance or copays, there is no really good way for manufacturers to provide copay assistance, because they are not allowed to do so,” said Roger Longman.

read full insight article >